First Ebola treatment trials to start in West Africa

0

Clinical trials to try to find an effective treatment for Ebola patients are to start in West Africa next month.

The medical charity Medicins Sans Frontieres, which has been helping lead the fight against the virus, says three of its treatment centres will host three separate research projects.

Meanwhile, Liberia’s President Ellen Johnson Sirleaf has lifted the state of emergency imposed in the country.

She warned “this is not because the fight against Ebola is over”.

It marks the progress being made in the country, where the weekly number of new infections is falling.

In a radio address she told the nation that night curfews would be reduced, weekly markets could take place and preparations were being made for the re-opening of schools.

One trial involves using the blood of recovered Ebola patients to treat sick people in the Guinean capital Conakry.

Two antiviral drugs will be trialled in Guinea and an unconfirmed location.

“This is an unprecedented international partnership which represents hope for patients to finally get a real treatment,” said MSF spokeswoman Dr Annick Antierens.

The Ebola outbreak is thought to have infected more than 14,000 people, almost all of them in West Africa. The death toll has risen to 5,160.

The first trials are due to start next month. Initial results could be available in February 2015.

The World Health Organization announced in September that experimental treatments and vaccines for Ebola should be fast-tracked.

Two experimental vaccines, produced by GlaxoSmithKline (GSK) and the Public Health Agency of Canada, have already been fast-tracked into safety trials.

The GSK vaccine is being tested in Mali, the UK and the US. Research on the Canadian vaccine is also under way in the US.

The three latest trials are:

At the Donka Ebola centre in Conakry, Guinea, led by the Antwerp Institute of Tropical Medicine (ITM), involving convalescent blood and plasma therapy – using blood from recovered patients containing antibodies that successfully fought off the virus to boost the patient’s immune system

At a site yet to be officially announced, funded by the Wellcome Trust and led by the University of Oxford, using the antiviral drug brincidofovir. It works by interfering with the virus’ ability to multiply. Up to 140 consenting patients will take the tablets twice a week over a two week period, and survival rates will be compared to those before the trial

In Gueckedou, Guinea, led by the French National Institute of Health and Medical Research (Inserm), using the antiviral drug favipiravir.
Around 400 people participate in the first trials and they will be extended to other centres if the early results are promising.

Prof Peter Horby, from the University of Oxford, said: “There’s a great need for these trials.

“There’s both the humanitarian need, a tragedy for individuals and for communities and we need to do everything we can to offer some hope to those communities.

“But there’s also scientific need, we have these products which may or may not work in patients with Ebola and the only way we can test them is during an epidemic.”

Follow Us

Previous articleNaira suffers worst depreciation in 3 years, lost 54k to dollar
Next articleQatar ‘ready’ to host African Cup of Nations

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.